Big Milestone: @PerimeterMed's Claire™ has received premarket approval (PMA) from FDA. This represents a massive leap forward in our mission to transform the standard of care for #BreastCancer patients.
Read more: https://t.co/bnpEkqoH7B
#PerimeterAI#StrongerTogether
Hear CEO @adrianvmendes chat about the future of breast conserving surgery.
Why do patients need second surgeries? What changes when surgeons have real-time answers? And how is AI helping solve tough problems in breast cancer care?
Link to listen 🔗https://t.co/RfRAZhAgip
Your Breast Density Matters, Here's Why:
When dense breast tissue is imaged on a standard mammogram, it appears white. So does cancer.
If you have dense breasts, talk with your doctor about advanced imaging options that help provide enhanced visibility.
#WorldDenseBreastDay
This #NationalSurgicalTechnologistWeek, we extend our deepest gratitude to incredible surgical techs whose precision, dedication & expertise make a difference everyday.
Proud to partner with professionals who set the gold standard for patient care. Thank you for all you do!
Perimeter Claire in the OR: Real-time margin assessment during lumpectomy using OCT imaging.
No dyes, drugs, or disruption. Surgeons get additional info and review margin imaging while patient is still in surgery before pathology confirms margin assessment, as always.
Engineering at Perimeter isn't just about making a good product, it's about how the product is going to impact someone's life. Alec Hill talks about why his work motivates him. See his full spotlight → https://t.co/gUtSm8heXp
We're hiring → https://t.co/bg4Omh0jkl
After a lumpectomy comes the wait for pathology. Clean margins ➡️ better outcomes, lower recurrence.
Claire images tissue in the OR, giving surgeons more info on margins during surgery.
#dcis#breastcancer
📌adjunc tool; does not replace histopath nor provide diagnosis.
We're proud to support Dr. Jennifer Tittensor and her team at @Intermountain Health as they bring this technology to their breast cancer patients.
Here's what that experience has been like, in her own words. 👇
#leadingtheway#patientcare#HelloClaire $PINK.V $PYNKF
This #SurgicalOncologistDay, we celebrate the skill, compassion & dedication of the surgeons who bring precision & hope to cancer care, changing lives every day.
Thank you for your impact in and out of the OR. 💙
Read more: https://t.co/VAUlKLdYFx
Note: This press release is intended for an investor audience. For more information about Claire, visit https://t.co/lYD8DyxoMn
Dr. Teresa Reading, breast surgeon at @Intermountain Health LDS Hospital, among the first in the US to use Claire: @PerimeterMed's FDA-approved, AI-powered imaging system, in the OR for breast cancer margin assessment.
Here's what that experience was like, in her own words. 👇
Utah, Say Hello to Claire.
The 1st FDA-approved, AI-enabled imaging device for intraop breast cancer margin assessment was used commercially for the very first time by Dr. Teresa Reading and Dr. Jennifer Tittensor at @Intermountain
https://t.co/VAUlKLewv5
$PINK.V $PYNKF #medtech
Snapshots from the field: our team is hard at work. Grateful for the people behind the mission — there's a lot in the works, and we're excited about where it's headed.
#DreamTeam#PerimeterAI
Your surgeon can walk through tools, techniques & margin eval. methods used during your procedure, so you can better understand what happens in the OR.
Prepared questions can lead to more confident conversations.
More info on @PerimeterMed's patient page. https://t.co/RsxajTd60J
Claire uses non-ionizing near-infrared light while keeping tissue intact for pathology evaluation. Follow our page to stay updated on our latest corporate initiatives.
📌Adjunc. tool; not replacement for histopath/diagnosis.
Claire delivers 10x higher resolution than standard intraoperative X-ray or ultrasound for breast cancer margins. Follow our page to stay up to date with @PerimeterMed.
📌Adjunc. tool; not replacement for histopath/diagnosis.
Claire™ is the first AI-powered imaging device for margin assessment during breast surgery approved in the U.S.
Follow our page to stay updated on our latest corporate initiatives.
📌Adjunc. tool; not replacement for histopath/diagnosis.
Great products start with understanding the problem. Maggie Sanati Burns, Product Director at @PerimeterMed talks about our mission & OCT+AI dev https://t.co/0WfPpptZBQ
📌Adjunc. tool; not replacement for histopath/diagnosis. Efficacy of Claire was evaluated after SOC completion